Viseven

NOVEMBER 9, 2022

From the ideation stage to the marketing of the drugs, the pharma market employs medical experts, researchers, and thought leaders. These professionals are known as the KOL (key opinion leader) in pharma industry. Who are key opinion leaders in pharma? The role of KOLs in the pharma market. Potential and expertise.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication Hospitals 52

pharmaphorum

APRIL 15, 2021

The pharma organisation prides itself on having an open, collaborative, “science first” approach to help ensure breakthrough discoveries have the very best chance of long-term success in bringing new treatment options to patients worldwide. When it comes to developing cutting-edge innovations, Astellas aims to be at the forefront.

Labelling 62

Labelling Communication FDA Pharmaceutical Companies 62

pharmaphorum

JANUARY 24, 2023

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Vaccines 98

pharmaphorum

MAY 10, 2022

In a panel discussion moderated by pharmaphorum editor in chief Jonah Comstock, they discussed the current state of healthcare communications, laid out the ingredients of good communication, and shared some success stories and advice for healthcare communicators in the pharma space. That’s a brand-new channel that wasn’t there 10 years ago.

Communication 96

Communication Prescription Filling Pharmaceutical Companies Pharmaceutical Companies 96

ISPE

SEPTEMBER 28, 2022

Emerging Leaders are encouraged to attend not only the educational sessions but also the international hackathon taking place the weekend prior to the event. To avoid employee burnout and reduce employee turnover, the industry needs to evolve with its changing employee expectations.

FDA 52

FDA 52

pharmaphorum

OCTOBER 12, 2022

He explains that bringing cutting-edge genomic therapies to market which could treat or cure life-threatening diseases can take up to 15 years and cost $2 billion – far too slow to match patients’ needs, and far too expensive on the healthcare system. “We

Immunization 102

Immunization Vaccines Pharmaceutical Companies Pharmaceutical Companies 102

Pharma Marketing Network

FEBRUARY 25, 2022

In a live conversation hosted by the DHC Group and the Pharma Marketing Network, Jeff Fayer (Director, Patient Experience Lead – CSU, Novartis) was joined by Mark Bard (DHC Group) , R.J. Across the industry, companies are working on solutions to the new hybrid reality facing teams and their leaders. Watch Full Event Here. Implication.

Communication 52

Communication 52

pharmaphorum

JULY 9, 2021

Luckily, Takeda is one of many companies in the sector looking into innovative ways to reduce or even eliminate the diagnostic odyssey for rare disease patients – often by leveraging global collaboration and innovative digital tools. We need to proactively reach out and work with other organisations and institutions.

Medical Records 121

Medical Records Hospitals FDA 121

pharmaphorum

SEPTEMBER 18, 2020

We take a look at the company’s story, from its creation as a merger of two equals, to its recent major restructuring and its drives in cutting-edge oncology and COVID-19. The profits from these products funded the development of new drugs, such as gastroesophageal treatment Losec and cardiovascular treatment Aptin.

Vaccines 115

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 115

ISPE

NOVEMBER 9, 2022

2022 ISPE International Emerging Leader Hackathon. 2022 ISPE International Emerging Leader Hackathon. Trudy Patterson. Wed, 11/09/2022 - 08:36. iSpeak Blog. Yanet Flor. Bennett-Kelley. Carolina Isabel Serrano Martinez. Shakti Nagpal. Silas Tamufor. Hamid Teimourian. 9 November 2022. And I owe this in the first instance to?ISPE

52

52

pharmaphorum

JANUARY 15, 2021

Pharma’s reputation is currently riding high as the industry comes together to tackle COVID-19, but GSK’s UK general manager Neale Belson says there is always more companies can do to build their culture and make sure employees and customers trust they are doing the right thing. There’s never been a better time to be in pharma.

Vaccines 105

Vaccines 105

pharmaphorum

AUGUST 31, 2021

For the healthcare ecosystem to drive research and care, clarity is needed about the opportunities and challenges of ECAs and their value in bringing therapies to patients faster, say COTA Viraj Narayanan and Karla Feghali from ConvergeHEALTH by Deloitte. Myth 1: There are too many challenges with adopting an ECA.

FDA 73

FDA Insurance Coverage Documentation Insurance 73

The Physician Pharmacist

OCTOBER 27, 2023

️ Prepare for an enlightening Episode 7 of The Physician Pharmacist Podcast Miniseries, where we sit down with Dr. Steven Berk, a seasoned Internal Medicine Physician with over 25 years of experience. The MCAT: Everything You Need To Know How Hard is Medical School Can you work while in Medical School?

Medical Schools 52

Medical Schools Medical Records Hospitals Patient Care 52

PQA

JUNE 7, 2023

Diverse Voices in Quality is a new PQA blog series that showcases the successful career paths and experiences of medication use quality professionals from diverse groups at PQA member organizations. I saw a gap that could be addressed through a new business. A lot of times people assume it's just me, but we have a team of six.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Medical Schools 52

pharmaphorum

APRIL 16, 2021

The launch environment was directly impacted by the COVID-19 pandemic, which hit two key drivers of launch uptake particularly hard: the dynamic market, i.e. new and switch prescriptions, and face-to-face interactive engagement with healthcare professionals. Here we assess the launches of New Active Substances (NAS) only.

Pharmaceutical Companies 86

Pharmaceutical Companies Pharmaceutical Companies Documentation Vaccines 86

Viseven

JULY 18, 2023

In healthcare, this score is known as the Net Patient Score, reflecting its specific application within the pharma niche. In the pharma niche, the Net Patient Score has gained recognition for its ability to assess patient loyalty and drive improvements in the quality of care. The use of NPS in healthcare offers several benefits.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Patient Care 52

pharmaphorum

NOVEMBER 24, 2020

IQVIA’s Sarah Rickwood explores how pharma can help healthcare systems address treatment backlogs caused by the COVID-19 pandemic. The pandemic’s aftermath is looking to stretch into the first half of the 2020s. Considerable time was devoted to the discussion of V- , U- and L-shaped recoveries.

Pharmaceutical Companies 74

Pharmaceutical Companies Pharmaceutical Companies Vaccines Chemotherapy 74

pharmaphorum

MARCH 30, 2021

Alexion’s senior vice president of its international business talks to Paul Tunnah about the importance of “people-centred and vulnerable” leadership, the surprising impacts of COVID and the promising future for treating patients with rare diseases. . I’ve seen that leadership is not just about the business.

Hospitals 110

Hospitals Communication Pharmaceutical Companies Pharmaceutical Companies 110

pharmaphorum

JANUARY 9, 2023

The Roman god Janus, as we are frequently reminded in January, was two faced and able to look forward to the coming year and backward to reflect on the past one. Africa, as a continent which imports up to 90% of its medicine needs, was especially exposed. Things fall apart: deglobalisation.

Vaccines 96

Vaccines Pharmaceutical Companies Pharmaceutical Companies Documentation 96

pharmaphorum

JANUARY 29, 2021

The future of life sciences CRM will be defined by rapid digital transformation and a focus on customer experience – and those who stick to old ways of working will be left in the dust, according to new research from Gartner. I don’t think it’s possible to go back from this. We can be far more flexible than we imagined,” he notes.

Medical Records 126

Medical Records 126

ISPE

MAY 8, 2023

When this column is published, we will have completed two very successful international conferences—the Facilities of the Future Conference and the Aseptic Conference—and the European Annual Meeting in Amsterdam will likely be concluded. We’ve accomplished much, and I’m left wondering, “Where has the year gone?”

Documentation 52

Documentation 52

pharmaphorum

JANUARY 16, 2023

The present article focuses on opportunity, the unmet need which lies at the heart of better healthcare provision, and two areas of growth and opportunity: Point of Care Diagnostics, and the new pharmacotherapy classes which will commercialise for the first time in 2023.

FDA 95

FDA Pharmaceutical Companies Pharmaceutical Companies Compounding 95

pharmaphorum

FEBRUARY 16, 2021

In this feature, Grünenthal’s Florent Eduoard and Kate Hurtig outline their principles for a new pharmaceutical marketing model. . “Keith, Kotler, Maslow” has long been the Holy Trinity of pharma marketing. This could be through a wise quote cracked in a meeting to give the right gravitas to any challenged proposal.

Health and Personal Care Stores 93

Health and Personal Care Stores Pharmaceutical Companies Pharmaceutical Companies Immunization 93

pharmaphorum

SEPTEMBER 3, 2020

Sarah Rickwood looks at how COVID-19 is changing pharma’s commercial models and launch strategies. Doctor’s capacity to address, and enthusiasm for, new launches may be limited unless those new launches are revolutionary in their field”. But that doesn’t mean we are completely flying blind.

Pharmaceutical Companies 83

Pharmaceutical Companies Pharmaceutical Companies 83

pharmaphorum

OCTOBER 20, 2020

Sarah Rickwood delves into IQVIA data to find out exactly how pharma’s HCP engagement has changed over COVID-19, and what the channel mix might look like after the pandemic. With in-person visits drastically reduced, pharma has been challenged to find ways to continue engaging effectively with HCPs via remote channels.

Pharmaceutical Companies 121

Pharmaceutical Companies Pharmaceutical Companies Documentation Communication 121

pharmaphorum

JANUARY 14, 2021

Preventing virus transmission, as well as “getting out of the way” of healthcare professionals pivoting to address the virus was key, and HCPs largely welcomed the way pharma reacted as responsible and necessary. Pharma moved rapidly to remote interactions, even to the point of all virtual launches of new products.

Pharmaceutical Companies 65

Pharmaceutical Companies Pharmaceutical Companies Labelling 65

pharmaphorum

JANUARY 5, 2021

Certain countries were also forced to respond by building new capacity-dedicated facilities for severe COVID-19 patients, like the largely unused “Nightingale” hospitals in the UK. “This may mean a change in patient journeys to pharmacotherapy becoming longer and more complex, but also occurring in different settings”.

Hospitals 105

Hospitals Vaccines Pharmaceutical Companies Pharmaceutical Companies 105

pharmaphorum

MARCH 28, 2022

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise antibodies for targeted therapies. . Once collaboration was decided upon, the companies gathered to define pharma’s biggest issues.

Compounding 98

Compounding 98

pharmaphorum

JANUARY 27, 2021

“A new medical affairs communication model is emerging that provides greater collaboration and stakeholder engagement”. The Medical Affairs function in the pharmaceutical industry has grown in importance in recent years, having a greater voice internally and becoming significant budget holders.

Communication 68

Communication Hospitals 68

ISPE

MAY 9, 2023

There was a brain drain as university graduates looked for opportunities outside the state. By the 1990s, pharmaceutical companies were looking to partner with contract research organizations (CROs) for drug development and clinical trials. These areas raise the question: How does an area become a hub for competing businesses?

Vaccines 94

Vaccines Pharmaceutical Companies Pharmaceutical Companies Medical Schools 94

pharmaphorum

FEBRUARY 16, 2022

Leela Barham and Neil Grubert look back at what was expected for market access in 2021 and look ahead at what 2022 could hold. The MHRA noted that applications have ranged from big to small pharma and from common to rare conditions but the top therapeutic areas were oncology, neurology and respiratory.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines 52